The scope and utility of phage display is reviewed with emphasis on medical applications and structure-based ligand and drug design, from literature mostly after 1994. General principles by which phage-displayed peptides achieve affinity and selectivity for targets are described, along with selected structural or mechanistic studies of the binding of peptides or proteins discovered or engineered by phage display. Such engineered proteins whose wild-type or mutant crystal or 2D-NMR structures yield insight about the basis for enhanced affinity or altered specificity include antibodies, zinc fingers, human growth hormone, protein A, and atrial natriuretic peptide. Structures of complexes of de novo phage-discovered peptide ligands with targets such as the Src SH3 domain, streptavidin, and erythropoietin receptor reveal the structural basis for receptor-peptide recognition in these systems.
Introduction
Phage display has rapidly matured as a widespread technology for harnessing the chemical and structural diversity of peptide libraries. Since its inception in 1985 (82) , phage display (reviewed in 10, 11, 14, 15, 17, 60, 67, 93) has revolutionized the discovery of novel peptide ligands that bind to diverse targets. Development of alternate biological systems for displaying combinatorial libraries (64, 85) promises to expand the technology. The power of phage display for screening libraries is twofold. First, the expressed fusion peptide or protein recognition elements are directly linked to the genes encoding their replication, allowing facile identification and amplification of binding sequences. Second, phage-displayed moieties usually exhibit the same or similar functional characteristics as their native counterparts in solution.
Because proteins and peptides are the natural substrates or ligands in ubiquitous biological events, phage display is an ideal tool for studying macromolecular interactions, central in both normal biological processes as well as in disease states. One active thrust in the pharmaceutical sector involves the discovery of peptide ligands as initial leads for subsequent drug development. The versatility of phage display has become apparent through discovery of peptide epitopes that bind to targets whose natural ligands or substrates are not only proteins or peptides, but also nonpeptides (34, 80) .
General Applications
Phage display of entire proteins, receptor domains (42) , or lectin chains or domains (27) enables the engineering of properties of natural proteins (reviewed in 67) without detailed knowledge of structure-function relationships. Such protein engineering is exemplified by the directed in vitro evolution of specificity of enzymes (58, 91) , of enzyme inhibitors (22, 61, 62, 85, 87, 88) , of DNA binding proteins (43, 58, 96) , and of enhanced affinities of cytokines for their receptors (77, 86) .
Substrate specificity mapping through presentation of peptides on phage as potential substrates (24, 83) has accelerated identification of highly active and selective substrates without any a priori assumptions about the specificity or physiological substrates. Finally, phage display affords a powerful tool for localization of epitopes of monoclonal (2, 5, 7, 84) and polyclonal (28) antibodies, and of many other binding proteins (18, 35, 38, (74) (75) (76) 94) .
Selected Medical Applications
SURROGATE PEPTIDE LIGANDS FOR RECEPTORS A small cyclic peptide identified by phage-display binds to five somatostatin receptor subtypes with nanomolar affinities (94) . Small peptides bind specifically to the cell surface immunoglobulin receptor of a human B-cell lymphoma cell line, and when conjugated into dimers or tetramers, kill these cells in vitro with 50% inhibitory concentrations (IC 50 s) between 40 and 200 nM, providing a model for peptidebased therapy (75) . Potent specific ligands for the human urokinase receptor, a key mediator of tumor cell invasion (34) , compete with urokinase for receptor binding with IC 50 s between 10 nM and 10 µM, providing leads in the discovery of drugs that inhibit cell-surface proteolysis.
TUMOR SUPPRESSOR PROTEIN (P53) AND INTEGRINS Mutations that alter the function of p53 comprise the most common genetic alteration in human cancers (18, 76) . The honed specificity of a phage-displayed p53-binding peptide allowed discrimination between wild-type and correctly folded single-site mutants of p53 (18). Targeting subpopulations of a heterogeneous p53 pool can be viewed as a key step in developing new diagnostics and therapeutics for treating cancers expressing mutant p53s.
Integrins are cell surface receptors that enable communication between the exterior and the interior of the cell necessary for anchorage and for redundant regulation of cell growth, differentiation, and migration (reviewed in 41). The integrin α v β 3 has been a target for discovery of small ligands by phage display (39, 54) , as it is involved not only in physiological processes such as angiogenesis and tissue repair, but also in pathological conditions such as osteoporosis, tumor cell metastasis, and adenoviral infection. Similarly, the α 5 β 1 and α IIb β 3 integrins have been the targets for peptide inhibition of tumor invasion and platelet aggregation, respectively (39, 54).
PHAGE-ANTIBODIES Optimization of high-affinity antibodies by phage display of combinatorial antibody libraries is a robust mimic of immune selection for natural antibody diversity, circumventing hybridoma and immunization technologies. Phage-antibodies have found broad application both in medical science (reviewed in 92) and in plant biology (reviewed in 16). Evolution of exquisite specificity of antibodies from large phage display repertoires is exemplified by a single-chain alloantibody developed as a diagnostic and therapeutic reagent capable of discriminating between two polymorphic forms of the α IIb /β 3 integrin differing by a single amino acid (36) Fabs isolated against a host of viral pathogens (reviewed in 12), including the human immunodeficiency virus type 1 (HIV-1; reviewed in 26), provide research tools, diagnostics, and potential pharmaceutical reagents for the prophylaxis and treatment of viral diseases. Physiologically relevant doses of a Fab isolated from a phage display library prepared from bone-marrow of a longterm, asymptomatic, HIV-1 seropositive donor provided complete protection against HIV-1 infection in a mouse model (68) . TAILORING SPECIFICITY THROUGH EPITOPE MASKING A recently developed phage display approach utilizes specific immobilized monoclonal antibodies to capture native viral proteins of extracts of infected cells (25). The method circumvents the use of purified glycoprotein antigens whose conformational integrity may be compromised during purification, and permits faster establishment of Fabs directed to multiple glycoproteins. The capture antibody, by masking an epitope on the captured antigen, restricts the specificity of the cloned Fabs to unmasked eptiopes. Sequential use of different capture antibodies allows tailoring the affinity of selected Fabs to specific regions and epitopes within the target viral proteins.
VACCINE DEVELOPMENT Random phage peptides selected against an antimucin core antibody defined the antibody's specificity and uncovered epitopes for cancer vaccine candidates (56). Using a highly potent and broadly reactive HIV-1 neutralizing antibody as the probe, Keller et al identified hundreds of reactive phage clones whose epitopes mimic the HIV-1 gp120 V3 loop, and which provide HIV vaccine candidate peptides (52).
The scope of phage display has expanded from applications involving targets of well-defined homogeneous molecules, to whole cells (13, 20, 29, 33) , to sera from clinically well-defined patients (15, 32, 66) , the latter to identify disease-specific epitopes without the need to identify the pathological antigen. Mimotope peptides that recognize antibodies of patients can be identified as candidates for vaccine development in the absence of purified monoclonal antibodies (15, 32, 66) . The phage itself is a suitable vector for immunogenic mimotopes (66) , and multifunctional phage displaying both B-and T-cell epitopes are superb immunogens (23, 66).
ORGAN TARGETING IN VIVO An organ-selective targeting approach based on in vivo screening of random peptide sequences identified peptides capable of mediating selective localization of phage to brain and kidney blood vessels (70) . The peptide sequences represent the first step towards identifying selective endothelial markers, with potential use in targeting cells, genes, and drugs into selected tissues. Cancer therapy was envisioned with drug conjugates directed at tumor vasculatures containing specific targetable markers.
GENERAL PRINCIPLES BY WHICH PHAGE-DISPLAYED PEPTIDES ACHIEVE AFFINITY AND SELECTIVITY FOR TARGETS

Core Residues of Small Peptides Determine Affinity
To completely sample all possible mutants that can be surveyed simultaneously (∼10 8 ), total randomization is limited to 4-6 residues due to codon degeneracy (14). Thus many searches for ligands are undertaken with random hexapeptide libraries. The binding sequences obtained from such libraries often exhibit a conserved subset or core of residues constituting a binding motif. For example, phage-displayed hexapeptides selected for binding to integrins (39, 53, 54) share the RGD sequence, and those selected for binding to concanavalin A (80) share the YPY sequence. In general, the role of residues flanking the conserved core sequences may be to provide peripheral, less specific interactions with the target, to exert a favorable influence on the conformation of the core motif, or to constrain its conformation through disulfides.
CONTINUOUS EPITOPES Sequences discovered by screening phage libraries are often identical to those of the recognition sequences of the corresponding natural ligands. The core consensus sequences of phage-displayed epitopes recognized by many monoclonal antibodies are similar to those of the epitopes of the proteins against which the antibodies were originally raised. Selection of semisynthetic antibodies by phage display has also been shown to produce sequences similar to those obtained from the natural selection process operating in the immune system. Thus, phage display can faithfully reproduce, reveal, and even improve on fundamental recognition elements in biology.
MIMOTOPES From a viewpoint of drug design, one property of ligands discovered by phage display that can be improved over corresponding natural protein ligands is their size. Because of the practical limitation in the length of peptide to be completely randomized (noted above), high affinity for targets of small phage-displayed peptides is often achieved through mimotopes whose shorter sequences differ from those of the natural ligands, yet mimic the specificity.
Appropriate Conformational Constraints Increase Affinity
DISULFIDE CONSTRAINTS A generally exploited principle to increase ligand affinity is to constrain the conformations of the unbound ligand to be the same as or similar to that of the protein-bound ligand (reviewed in 30). Increased affinity of constrained ligands compared with more flexible counterparts is thus achieved, owing to a decrease in the conformational entropy in the unbound state. Such constrained peptides have further key advantages in structure-based drug design because they are amenable to structural determination in solution. Thus, disulfide constraints have been used in the discovery of high-affinity cyclic peptide ligands (34, 39, 53, 54, 69, 79, 94) .
A phage-displayed hexapeptide library against α 5 β 1 integrin (54) yielded a potent disulfide-bridged RGD-containing peptide. Cyclic ligands, some constrained by two disulfides, selective for four different integrins, were discovered in cysteine-flanked penta-, hexa-, and heptapeptide libraries (39) . A cyclic peptide with two disulfides was 20-fold more potent in inhibiting the attachment of α v β 3 or α v β 5 integrin-expressing cells to vitronectin than a corresponding peptide with one disulfide, and 200-fold more potent than linear counterparts. By selecting ligands against RGD-containing fibronectin fragments (instead of against the receptor, as above), the same group discovered a disulfidebonded octapeptide that bound specifically to fibronectin and RGD-containing fibronectin fragments (69) .
PROTEIN SCAFFOLDS The four-helix bundle framework of cytochrome b562, in which two loops were randomized (55), afforded mutants that bound a bovine serum albumin-hapten with a K d of ∼1 µM, which is comparable to that for a monoclonal antibody directed against the conjugate (0.29 µM). Tendamistat, a β-sheet protein inhibitor of α-amylase, was used as a scaffold for constraining peptides displayed on the loop regions to isolate mutants that bound specifically to a monoclonal antibody (65) . A potent and specific interleukin-6 antagonist was developed from a novel 61-residue β-sheet "minibody" scaffold corresponding to the variable domain of immunoglobulins, bearing two hypervariable loops optimized by phage display (63) . Optimization of hypervariable loops on phage-displayed on Fabs or single-chain antibodies also yields conformationally constrained libraries; Figure 1 (See color insert) shows the structure of a trisaccharide-single-chain antibody complex in which the six complementarity-determining loops were randomized to increase affinity for the carbohydrate antigen (21).
CONFORMATIONALLY HOMOGENEOUS LIBRARIES Libraries of peptides with predetermined secondary structure can provide a conformational model of the peptide pharmacophore directly from screening, thus allowing the design of a suitable nonpeptidic scaffold to replace the peptide backbone in a process termed selection-driven peptidomimetic design (5). A conformationally homogeneous peptide library was produced from a structure-inducing template by randomizing five positions occupying the solvent-exposed region of an eightresidue α-helical portion of a zinc finger motif ( Figure 2 , see color insert). Coupling zinc coordination with formation of a defined zinc finger motif structure provided a built-in filter against selection of undefined or nonnative structures among the zinc-dependent ligand binding sequences in this library. Screening against a monoclonal antibody yielded a well-defined consensus sequence exhibiting strong, zinc-dependent binding to the antibody. The secondary structure of a selected binding variant was shown to be equivalent to that of wild type. Conformationally homogeneous libraries were considered advantageous when no structural information is available at the outset of a drug discovery project.
MOLECULAR BASIS FOR AFFINITY AND SELECTIVITY OF PHAGE-DISPLAYED PROTEINS
Visualization of Receptor-Ligand Interactions
Although the number of systems studied by phage display has burgeoned, many fewer studies address the molecular basis by which either de novo peptides or randomly mutagenized proteins develop affinity or specificity. The most powerful and direct method for visualizing the interactions responsible for binding is determination of the structure of the ligand-target complex, by X ray or neutron crystallography, or by 2D NMR. When the structure of the targetnatural ligand complex is known, modeling how alterations in the sequence of the natural ligand affect its interactions with the target may provide insight into the affinity changes effected by phage display. Finally, in the absence of the structure of the target, determination or modeling of the structure of the binding peptide or protein alone may provide insight into the determinants of affinity and selectivity.
Affinity-Matured Human Growth Hormone
The affinity of human growth hormone (hGH) for its receptor has been improved by phage display (86) . Five selected regions, each comprising four residues known to contribute to binding from alanine scanning mutagenesis, were separately mutagenized and mutants of higher affinity identified. Combination of 15 mutations yielded a hormone with a 400-fold cumulative increase in affinity, which also exhibited an improved physicochemical property: better diffraction of crystals of the mutant (86) .
Comparison of the crystal structures of the wild-type and mutant hormones (Figure 3 , see color insert) showed that most of the secondary structural elements are unchanged. A 3.0-Å shift in the main chain between residue 54 and minihelix 1 was attributed to a change of buried Phe54 to Pro. Conversion of Phe10, buried in the four-helix core of wild type, to Ala causes a rigid body rotation of ∼12
• of helix 1 to bring its N terminus closer to helix 4. In addition, the C terminus of helix 4 moves by ∼1.1Å toward helix 1. The space produced from these shifts is filled by a water molecule, completely buried in the hydrophobic core (hydrogen bonded to two carbonyl oxygens). Because most of the binding determinants for the high-affinity receptor occur on the solvent accessible surface of helices 1 and 4, the Phe10 → Ala substitution was identified as a potentially critical determinant of the enhanced affinity. Four other substitutions at residues whose side chains are largely buried in wild type do not cause any conformational differences but exert indirect effects on the binding affinity, possibly by altering flexibility. Nine substituted residues were found at the receptor-hormone interface in the wild-type complex.
Minimization of the Size of Natriuretic Peptide and of a Binding Domain from Protein A
A combination of phage display, modeling, and alanine scanning mutagenesis was used to reduce the size of natriuretic peptide (ANP), a hormone regulating blood pressure and salt balance, from a 28-to 15-residue peptide retaining high biopotency (57) . Alanine scanning mutagenesis of ANP displayed on phage identified seven residues most critical for receptor binding. Guided by the 2D-NMR structure that showed that five of the critical residues form a cluster defining a face of the molecule, Li et al replaced the native disulfide of ANP with a disulfide that placed the cluster of critical residues onto a smaller disulfidebonded cyclic-peptide portion. The 100-fold decrease in binding affinity due to the nonnative disulfide was restored by optimizing noncritical residues by phage display. The nine carboxyl residues were then deleted, and the peptide was again reoptimized by phage display. Finally, the four N-terminal residues were deleted to yield a 15-residue peptide whose affinity for the receptor (5.9 nM) was about sevenfold weaker than that of the wild type (0.8 nM). The successful reduction of the size of the ANP hormone demonstrates the power of phage display when guided by a 2D-NMR structure of the hormone alone in the absence of a structure of the receptor-ligand complex.
A similar approach used a protein A-immunoglobulin-Fc crystal structure and iterations of structure-based design and phage display. The Z-domain of protein A was minimized from a 3-helix bundle of 59 residues that binds to the Fc fragment with a K d of 10 nM, to a 2-helix bundle of 33 residues that binds with a K d of 43 nM (8).
Structural Plasticity in Phage-Displayed Fabs
A variety of CDR1 sequences were isolated (81), which imparted affinities for digoxin similar to that of the wild-type monoclonal antibody, including two of higher affinity by 4.1-fold (K d = 4.6 × 10 −11 M) and 1.8-fold (K d = 1.0 × 10 −11 M). The crystal structure of the wild-type Fab-digoxin complex shows that antigen recognition occurs exclusively by shape complementarity (45). From this structure, it was concluded that significant local main-chain rearrangement occurs in some of the mutants and that the CDR1 is more plastic than anticipated. 
Dimerization Improves Single-Chain Antibodies
DNA Recognition by Phage-Displayed Zinc Fingers
Zinc finger mutants whose specificities were tuned either to wild-type or altered operator DNA sequences were engineered by phage display (43) . Four residues mediating DNA binding in the finger of helix 1 of the murine transcription factor, Zif268, were identified for random mutagenesis from the crystal structure of the Zif268-DNA complex (71) (Figure 4 , see color insert). The altered sequences were related to interactions in the crystal structure of the wild-type protein-DNA complex and to the predicted structural changes incurred by alterations in the sequences of selector DNA operators. Zinc fingers capable of distinguishing operator sequences differing by a single base change were isolated.
Observation of Arg at position 6, in all isolates selected with operators containing a 5 guanine (G) in the 3 triplet [either guanine-thymine-guanine [GTG] or guanine-cytosine-guanine (GCG)], was attributed to the requirement for a charged hydrogen bond donor to interact with the 5 guanine, as seen in the X-ray structure of the native protein-DNA complex (Figure 4) . Alteration of the 5 G to T in this target triplet resulted in a complete consensus for Lys at position 6. Complementary charged pairs or charged-neutral pairs were always found at position −1 and 2 of the protein, which suggests the importance of maintaining intramolecular interactions such as the salt bridge between Arg and Asp at these positions in the wild-type crystal structure (Figure 4a) . Selection of clones directed to the GTG 3 triplet compared with GCG led to isolation of clones in which side chains at position 3 larger than Ser were excluded by the methyl group of thymine. Finally, DNA sequence changes that were nearby, but not in direct contact with the protein, affected the amino acid preferences in the zinc-finger mutants.
The specificity of each of the three fingers of Zif268 was also altered by Wu et al (96) , who randomly mutagenized six residues in each of the three fingers and then measured and compared affinities and kinetics of binding of selected proteins by surface plasmon resonance. Changes in the specificity of the fingers were generally governed by changes in the stability of the protein-DNA complex as reflected in the the rate of dissociation of the protein from DNA (k off ) values. The sequence of the finger 1 mutant with the highest affinity and selectivity for wild-type DNA differed radically from that of the wild-type protein. Also, because many of the selected mutants contained a Pro in regions that are α-helical in wild type, it was concluded that the secondary structure of this region may be altered in these proteins, and thus there is no single general coding relationship between zinc finger protein and target DNA sequence.
Modularity of the zinc finger domain was considered from the viewpoint of fusing individually selected domains to produce molecules potentially capable of recognizing any DNA sequence; a unique site in the human genome could be targeted by a six-finger complex. The functioning of such zinc fingers as positive or negative genetic switches was envisioned in the context of developing specific antiviral or antitumor agents (96).
MOLECULAR BASIS FOR AFFINITY AND SELECTIVITY OF DE NOVO PEPTIDES DISPLAYED ON PHAGE
L-and D-Peptide Ligands to the Src SH3 Domain
The Src homology 3 (SH3) domain, a 50-residue domain present in many cellular proteins, mediates intracellular signal transduction that is important for cell growth, migration, differentiation, and responses to the external environment. Pathogens also exploit interactions mediated by SH3 domains by mechanisms recently reviewed (6). Targeting the SH3 domain with pharmaceuticals that mimic the natural ligand-binding motif is a means of blocking specific cellular events to modulate both physiologic and pathological processes. SH3 binding motifs and determinants of binding specificity for Src, Fyn, Lyn, Yes, Abl, and phosphatidylinositol 3-kinase were elucidated by phage display (75) . Cyclic, disulfide-bridged D-peptide ligands to the SH3 domain were also identified by "mirror-image phage display," which involves chemical synthesis of the SH3 domain in the D-amino acid configuration, followed by selection from a phage display library expressing random L-amino acid peptides (79) .
Two types of SH3 domain L-peptide ligands (class I and class II) have been identified. Class I ligands, identified both by phage display and by a biased peptide library, have the consensus sequence RXLPPLP. Class II ligands, identified by a biased peptide library, have the consensus sequence PPLPXR ( is a hydrophobic residue). 2D-NMR structures (31) 
Binding of Diverse Phage-Displayed Sequences to HLA-DR1
The major histocompatibility complex (MHC) class II molecules are highly polymorphic membrane glycoproteins that bind peptide fragments of proteins and display them for recognition by T lymphocytes to generate an immune response (38, 44) . Crystallographic analysis of endogenous peptides associated with human leukocyte antigen DR (HLA-DR1) show that binding is mediated by 14 hydrogen bonds between the peptide main chain and MHC side chains. The hydrogen bonds, along with location of MHC pockets, induce the peptide to adopt a polyproline II conformation.
The crystal structure suggests two components to the mechanism by which MHC class II molecules form tightly bound complexes with peptides of diverse sequences. One component involves interactions with specific peptide side chains of the MHC pockets, many of which can accommodate a number of different side chains, thereby reducing the restrictions placed on the binding sequences. These pockets probably recognize the conserved and allele-specific anchor residues identified by phage display for three different (HLA-DR) molecules (38) . The second component to peptide binding involves conserved MHC residue interactions with the peptide main chain, providing a set of interactions that are independent of the peptide sequence and MHC polymorphism.
Combining Phage Display with Structure-Based Design in the Streptavidin Model System
As a paradigm for understanding how de novo peptides discovered by phage display achieve high affinity and selectivity, my colleagues and I have used streptavidin as a model receptor to identify high-affinity (K d ∼ 0.4 µM) disulfidebridged cyclic peptide ligands (34) , and to determine crystallographically the molecular basis by which the ligands are recognized (46). Streptavidin, a tetrameric protein secreted by Streptomyces avidinii, functions as an antibiotic by binding its natural nonpeptide ligand, biotin (vitamin H) with one of the highest known affinities (K d = 10 −14 M) for a noncovalent interaction. The choice of streptavidin as a model receptor was also guided by an objective to probe the structural relationship between peptide and nonpeptide ligands bound in a common site of a single target. Such information could provide insight into the principles involved in converting initial peptide leads (either the natural known substrates or ligands of a target, or those discovered by phage display) into small molecule drugs.
The streptavidin-bound crystal structures of two disulfide-bridged cyclic peptides (cyclo-Ac-[CHPQGPPC]-NH 2 , and cyclo-Ac-[CHPQFC]-NH 2 ) (Figure 6 , see color insert) and of a linear peptide (FSHPQNT) showed that the bound ligands share a common HPQ conformation and make common interactions with streptavidin, although significant differences in structures and interactions occur for flanking residues (46). In all complexes, bound peptides adopt a type I β-turn reflected by a hydrogen bond between the His main chain carbonyl and the main-chain amide NH of the i + 3 residue in the bound cyclic peptides. In bound cyclo-Ac-[CHPQFC]-NH 2 , there is an additional hydrogen bond, indicative of an α-helix, between the main-chain His carbonyl and the main-chain C-terminal Cys amide. Location of the disulfides of the bound cyclic peptides on the surface is consistent with their proposed entropic effect on binding (34); they do not interact with the protein and thus do not directly contribute enthalpically to the binding. Binding interactions for both cyclic and linear peptides include hydrophobic interactions, direct hydrogen bonds, and hydrogen bonds mediated by water molecules that play an integral role in the binding of the peptide ligands. The directionalities of all hydrogen bonds mediating binding of both the linear and cyclic peptides could be unambiguously determined (Figure 7 ).
MECHANISM OF BINDING Plasmon resonance measurements showed that the affinities of the HPQ-containing peptide ligands decrease significantly below pH ∼ 6.3, but they remain relatively constant above pH ∼ 6.3 (48). The structures of the streptavidin-bound peptides determined at pHs ranging from 2.0-10.5 indicated that at all these pHs, the His of the peptide is uncharged; there is a hydrogen bond between Nδ1 and the Gln amide proton (Figures 6 and  7) . Thus, deprotonation of the peptide His is required for high-affinity binding.
STRUCTURE-BASED DESIGN The structures of the complexes enabled structurebased design of high-affinity streptavidin-binding ligands conformationally constrained by thioether crosslinks, which have some advantages over disulfides (49). The relationship between the structure of streptavidin-biotin and of streptavidin-cyclic peptide ligands enabled design of a small organic ligand, glycoluril, with a K d of 2.5 µM and with structural features common to both biotin and the cyclic peptide ligands from which it was designed (50). Streptavidin also proved to be an ideal model system for applying phage display to development of receptor dimerizing agents. Topochemical crystal lattice-mediated dimerization, through disulfide interchange, of adjacent cyclo-Ac-[CHPQGPPC]-NH 2 ligands bound in either the I222 (51) or I4 1 22 (47) lattices produced ligand dimers that dimerized streptavidin.
Small Peptide Agonist Dimerizes EPO Receptor
Dimerization triggers many important biological processes (4; reviewed in 1, 40) . The action of the hGH receptor relies on dimerization of the cytokinebinding domains to produce a 1:2 cytokine-cytokine receptor complex that has approximate C2 symmetry (involving a rotation) (reviewed in 90). Receptor dimerization is also induced by erythropoietin (EPO) (89), a protein that regulates the proliferation and differentiation of immature erythroid cells. Recently, phage display has been applied to the development of an EPO-receptor dimerizing agonist peptide, a 20-residue disulfide-bridged ligand, unrelated in sequence to EPO. The peptide competes with EPO in receptor binding assays, induces cellular proliferation of EPO-responsive cell lines, and exhibits significant erythropoeitic effects in mice (95) .
Crystallography showed that the peptide forms a 2:2 complex with the receptor (59) . The peptide monomers are associated through a contact surface area of 320Å 2 formed by twofold related hydrophobic cores and by hydrogen bonds between twofold related β-sheet segments. A portion of each peptide monomer interacts with both receptors. The peptide and receptor dimers bury 840Å 2 and 880Å 2 of surface area, respectively, in the complex. The peptide dimer provides hydrophobic interactions, mostly from its hydrophobic core and hydrogen bonds, primarily linking the two twofold-related β-turns to the receptors. Interactions provided by the receptor are from recognition loops equivalent to those in the hGH-hGH receptor structure. However, the dimer assembly differs markedly from that of the hGH receptor complex, suggesting that more than one mode of dimerization can induce signal transduction and cell proliferation. Through the powerful combination of phage display and crystallography, discovery of a small EPO mimetic, followed by determination of its mode of interaction with the EPO receptor, now provides a structural foundation for development of a nonpeptide, small-molecule drug for anemia.
CONCLUSIONS
Phage display stands out as an icon of modern molecular biology. In many systems, it has been tightly coupled to drug discovery and has had a significant impact on medical science. Targets have been successfully extended from homogeneous molecules to whole cells, to sera, and finally to organs in vivo. The mirror-image phage display approach promises to further extend the technology by allowing identification of metabolically stable D-peptide ligands to small synthesizable proteins. The structural basis for recognition of phage-displayed peptides for targets has been probed in a number of systems. The future will surely bring more applications and innovations in the technology for probing biological processes and identifying drug leads, as well as more structural and mechanistic insights into the molecular basis whereby phagedisplayed peptides and proteins achieve affinity and selectivity for their targets.
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